Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid β precursor protein and with the suppression of nuclear factor-κB

Molecular Endocrinology

Volumn 14, Issue 1, 2000, Pages 147-159

  Lezoualc'h, Frank ^a,b   Engert, Stefanie ^a   Berning, Barbara ^a   Behl, Christian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DNA BINDING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HIPPOCAMPUS; NEUROPROTECTION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOPTOSIS; BUTHIONINE SULFOXIMINE; CELLS, CULTURED; CEREBELLUM; CHROMATIN; CORTICOTROPIN-RELEASING HORMONE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HIPPOCAMPUS; HUMANS; HYDROGEN PEROXIDE; IN SITU NICK-END LABELING; MICE; NEURONS; NF-KAPPA B; OXIDANTS; OXIDATIVE STRESS; PITUITARY GLAND; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 0034463102     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.14.1.147     Document Type: Article

References (61)

1. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin
2. Physiology and pharmacology of corticotropin-releasing factor
3. Neurobiology of corticotropin releasing factor (CRH) receptors and CRH-binding protein: Implications for the treatment of CNS disorders
4. Antidepressants and hypothalamic-pituitary-adrenocortical regulation
5. Expression cloning of a human corticotropin-releasing-factor receptor
6. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid
7. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations
8. Reciprocal changes in corticotropin-releasing factor (CRH)-like immunoreactivity and CRH receptors in cerebral cortex of Alzheimer's disease
9. CSF corticotropin-releasing factor (CRH) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites
10. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease
11. Amyloid plaque core protein in Alzheimer disease and Down syndrome
12. Alzheimer's disease: Its proteins and genes
13. Amyloid, the presenilins and Alzheimer's disease
14. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide
15. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein
16. Hydrogen peroxide mediates amyloid β protein toxicity
17. Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts
18. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein
19. The expression of amyloid β protein precursor protects nerve cells from β-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix
20. Synaptotropic effects of human amyloid β protein precursors in the cortex of transgenic mice
21. Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis
22. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
23. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C α
24. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation
25. Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease
26. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells-suppression of NF-κB and neuroprotection by antioxidants
27. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1
28. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-κB
29. Function and activation of NF-κB in the immune system
30. The NF-κB and IκB proteins: New discoveries and insights
31. Inhibition of NF-κB/rel induces apoptosis of murine B cells
32. An essential role for NF-κB in preventing TNF-α-induced cell death
33. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death
34. Suppression of TNF-α-induced apoptosis
35. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of apoptosis
36. Janus faces of NF-κB: Neurodestruction versus neuroprotection
37. Transcription factor NF-κB: Friend or foe of neurons?
38. Functional corticotropin-releasing factor receptors in human neuroblastoma cells
39. Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders
40. Oxidative stress, glutamate, and neurodegenerative disorders
41. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation
42. Regulation of kainate receptors by cAMP-dependent protein kinase and phosphatases
43. Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein
44. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship
45. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion
46. Methods for detecting and quantifying apoptosis
47. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry
48. Homology of the amyloid β protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease
49. Coupling of a signal response domain in IkBa to multiple pathways for NF-κB activation
50. Oxidative stress-induced apoptosis - An overview
51. Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL-60 cells
52. Memory-enhancing effects of secreted forms of the β-arnyloid precursor protein in normal and amnestic mice
53. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides
54. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB-mediated transcription
55. Neuroprotection by corticotropin releasing factor during hypoxia in rat brain
56. Corticotropin releasing factor antagonist reduces ischemic hippocampal neuronal injury
57. Corticotropin-releasing factor antagonist inhibits neuronal damage induced by focal cerebral ischaemia or activation of NMDA receptors in the rat brain
58. Toxicity of ricin and volkensin, two ribosome-inactivating proteins, to microglia, astrocyte, and neuron cultures
59. Identification and characterization of a 3′,5′-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promotor
60. Melatonin prevents oxidative stress-induced cell death in hippocampal cells
61. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells